Aura Biosciences, Inc. AURA R2KR3KPHARMA
Company Overview
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.05.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -12.86% |
| 6 Months: | -13.34% |
| 3 Months: | -12.01% |
| 1 Month: | +2.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AURA Aura Biosciences, Inc. R2KR3KPHARMA | 6.30 | -3.60 | $653.34M | 0.00% | -74.67% | -53.49% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.04M | 28.61M | 27.91M | 27.24M | 34.87M |
| Operating Income | - | - | -3.63M | -5.93M | -8.80M | -8.89M | -12.81M | -13.82M | -16.05M | -19.44M | -20.28M | -20.49M | -22.31M | -22.76M | - | -29.04M | -28.61M | -27.91M | -27.24M | -34.87M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.74M | -28.33M | -27.63M | -26.96M | -34.59M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.46M | -26.97M | -26.10M | -25.54M | -33.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00K | 48.00K | 26.00K | 15.00K | 11.00K |
| Net Income | -7.51M | -6.16M | -3.63M | -5.93M | -8.85M | -8.84M | -12.84M | -13.47M | -15.90M | -17.47M | -18.30M | -18.51M | -19.71M | -20.34M | - | -27.48M | -27.02M | -26.13M | -25.56M | -33.69M |
| Diluted EPS | - | - | - | - | -28.53 | -28.33 | -0.44 | -0.46 | -0.54 | -0.46 | -0.48 | -0.48 | -0.40 | -0.41 | -0.42 | -0.55 | -0.47 | -0.40 | - | -0.50 |
| R&D Expense | - | - | 2.85M | 4.18M | 6.63M | 6.37M | 8.28M | 9.51M | 11.29M | 14.40M | 15.12M | 15.43M | 17.05M | 16.88M | 17.04M | 23.34M | 22.88M | 22.18M | - | 27.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 60.30M | 84.99M | 96.12M | 112.79M |
| Operating Income | -22.21M | - | -60.30M | -84.99M | -96.12M | -112.79M |
| EBITDA | - | - | -59.12M | -83.70M | -94.89M | -111.66M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -58.76M | -76.27M | -86.81M | -106.08M |
| Tax Provision | - | - | 0 | 137.00K | 112.00K | 108.00K |
| Net Income | -22.21M | - | -58.76M | -76.41M | -86.92M | -106.19M |
| Diluted EPS | - | - | -1.96 | -1.93 | -1.75 | -1.76 |
| R&D Expense | 18.04M | 25.16M | 42.24M | 65.23M | 73.30M | 90.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.10M | - | 223.94M | 255.07M | 182.50M | 169.43M |
| Current Assets | - | - | - | 196.70M | 231.79M | 160.62M | 149.74M |
| Cash & Equivalents | - | 17.39M | - | 121.58M | 41.06M | 31.69M | 59.52M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.74M | - | 28.35M | 29.23M | 30.53M | 32.52M |
| Current Liabilities | - | 2.66M | - | 10.46M | 12.36M | 14.91M | 18.38M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 20.86M | 19.56M | 18.77M | 17.38M |
| Total Equity | -87.41M | -108.71M | - | 195.58M | 225.85M | 151.97M | 136.91M |
| Shares Outstanding | - | - | - | 37.77M | 49.35M | 50.00M | 63.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.32M | - | -54.60M | -63.85M | -79.81M | -84.74M |
| Investing Cash Flow | -771.00K | - | -67.87M | -113.96M | 68.82M | 35.59M |
| Financing Cash Flow | 10.04M | - | 95.63M | 97.29M | 1.59M | 77.16M |
| Capital Expenditure | -771.00K | - | -1.09M | -709.00K | -1.25M | -447.00K |
| Free Cash Flow | -25.09M | - | -55.70M | -64.56M | -81.06M | -85.19M |
| Net Change in Cash | - | - | -26.84M | -80.52M | -9.39M | 28.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 20.4% | - | -30.0% | -33.8% | -57.2% | -77.6% |
| ROCE % | -114.2% | - | -28.2% | -35.0% | -57.4% | -74.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 9.19% | 9.53M | $62.35M |
| 2 | Montanova Capital LLC | 6.95% | 7.21M | $47.13M |
| 3 | Frazier Life Sciences Management, L.P. | 6.85% | 7.10M | $46.43M |
| 4 | Long Focus Capital Management, LLC | 4.94% | 5.12M | $33.48M |
| 5 | Blackrock Inc. | 4.54% | 4.71M | $30.79M |
| 6 | Adage Capital Partners GP L.L.C. | 4.47% | 4.64M | $30.35M |
| 7 | Caligan Partners, LP | 4.14% | 4.30M | $28.11M |
| 8 | Vanguard Capital Management LLC | 3.95% | 4.10M | $26.82M |
| 9 | FCPM III Services B.V. | 3.91% | 4.05M | $26.51M |
| 10 | Orbimed Advisors LLC. | 3.21% | 3.33M | $21.80M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AURA
Aura Minerals Inc. (AUGO) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1IcktUSVhEQnMxOXVSMzJOX0R1SGg4b0V3alJRSmF5dWdqc1hhTUV5czFXeGMwNEYzUVNVZXotTVFXWVQwc0x4cHJDSjVOUTB1dEE?oc=5" target="_blank">Aura Minerals Inc. (AUGO) Stock Price, News, Quote & His…
Aura Minerals (AUGO) Hits Record Production, Is The Stock Still Trading At A Discount? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOd0ltenVNbWtIZ01BZUpiUG1lMEhyMS1vTTdaTXZqeFBYaTloQ1BsN05TcVJOMTBoSnJLdV9BTV9KM2s5RVM4UGs4Y2sxWnFmc1pScWw0d3pNaFNsTEE3MzE0dzlnZkdJVktYVnZjU2lqZjBQaHBITTJhTDNKN3BLSzNvLXg1bThmZlZUaz…
Aura Biosciences grants equity inducement awards to three new executives - scanx.trade
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPeG9YYjNNaHJVY3lXSEJNcjd5VDZfTWpMcUxYX1BtaHFKQnY5MTluazg4dExJcTJZZ1NVWm1LU2ZvSlcyZmVHSWpkZDdRa3NPclpXRFRYN2JNSmVYVlRUZDE3VDk5UDVrWWNldUlGVlhYZE16eE91dG4wRWZaZi1rTm5ZNFpTZHItVVdhWT…
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOYm1oWDhfeW1JVUt2ekctZTZ2ZlRWc1RMcEN3WEpqc1E2a3hVMzR1aXdOWWVxdmpPNXAtbjNnM09MUk5FRmxrU2ZNcnA4SDdtVGtCUXNTMU9TX1RzMHdqSGhobnJUXzc3eDU3OXlnLUxTUjZ3Rl9zbzdTdmxnOXdMUXVGS1gzX0xvQmctZ0…
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPZVZuOFVZbXJ0alp5WEpfZ3NjMmF5di15RmFUMGc5Ym55akw1RHBQTVV6ZFFlS3ZTWkxHSzJxY2VxMEFUa29seU1jbUJ5NnZWYkN4VDFad2JHcXE3U1Y5SWVQckNCdmVCaktSRXcxdUtPMzF5dk9LVG9qcWJjYU5vU1BTOEV1ZFRrX3pBU0…
Aura Minerals Inc. (AURA33.SA) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1RMThZSFBiN3RBWTVSQ3YwcEZ0RU5NNVlOaXVjYk52TXMyNEFWM3hJUDJobl9HTnhpQ2gxb1BUVXVCVm05MkFtTXFhQVlhaWZ0NmRfS0VZcE8?oc=5" target="_blank">Aura Minerals Inc. (AURA33.SA) stock price, news…
AURA — Frequently Asked Questions
What is the current share price of Aura Biosciences, Inc. (AURA)?
As of 2026-10-23 16:27 PDT, Aura Biosciences, Inc. (AURA) trades at $6.30 on NasdaqGM. Its 52-week range is $4.97 to $8.90.
What is the market capitalisation of AURA?
Aura Biosciences, Inc. (AURA) has a market capitalisation of $653.34M on NasdaqGM.
What is the P/E ratio of AURA?
AURA trades at a trailing price-to-earnings (P/E) ratio of -3.60. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.15.
What is the return on equity (ROE) of AURA?
AURA has a return on equity (ROE) of -53.49%. Its return on capital employed (ROCE) is -74.67%.
Is AURA a good stock to buy?
This page provides a data-driven analysis of Aura Biosciences, Inc. (AURA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.